Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. [electronic resource]
- Future oncology (London, England) Mar 2020
- 417-425 p. digital
Publication Type: Journal Article
1744-8301
10.2217/fon-2019-0647 doi
Adult Biomarkers, Tumor--genetics Child Drug Resistance, Neoplasm--genetics Humans Membrane Glycoproteins--antagonists & inhibitors Molecular Targeted Therapy Neoplasms--drug therapy Oncogene Proteins, Fusion--genetics Protein Kinase Inhibitors--therapeutic use Pyrazoles--therapeutic use Pyrimidines--therapeutic use Receptor, trkA--antagonists & inhibitors Receptor, trkB--antagonists & inhibitors Receptor, trkC--antagonists & inhibitors Treatment Outcome